Neprosynergy

590 Broadview Place NE Atlanta, GA 30324

+1 423 943 4265

BUILDING PARTNERSHIPS

NephroSynergy has built an extensive network of partners throughout the nephrology and clinical research community. This partnership includes over 400+ sites that specialize in every therapeutic area of nephrology, key opinion leaders and physicians that consult in every sub-specialty of nephrology, vendors and monitors that have comprehensive experience within the nephrology space, sponsors and CROs dedicated to furthering therapies for kidney disease, and a team that is entirely dedicated to renal research excellence.

Your Nephrology Specialists

FULL SERVICE NEPHROLOGY CRO

FULL NETWORK OF CERTIFIED RENAL SITES

NETWORK OF TOP KOL CONSULTANTS AND REFERRALS

FULL SERVICE NEPHROLOGY CRO

FULL NETWORK OF CERTIFIED RENAL SITES

NETWORK OF TOP KOL CONSULTANTS AND REFERRALS

Our Advantages

NephroSynergy provides solid FDA representation and has the experts and capacity to represent sponsors before the appropriate FDA committees. We have extensive experience with large and small Pharma., Device, Biotech and Clinical Research Organizations (CRO). These advantages and more provide our clients with a start-to finish, or anywhere in between, clinical trial solution in nephrology.

NEPHROSYNERGY IN THE NEWS

More Top Research From Kidney Week 2020

The American Society of Nephrology’s virtual Kidney Week featured a slew of research advancements and options for the treatment of chronic kidney disease (CKD). Some of the new findings presented included the investigational anti-mineralocorticoid agent finerenone for the slowing of CKD, new insights into dapagliflozin’s (Farxiga) renoprotective and cardioprotective benefits, and the best course of treatment for primary membranous nephropathy.

Regional Citrate vs Systemic Heparin: Which Is Better for Dialysis Filters?

Among critically ill patients with acute kidney injury, anticoagulation with regional citrate lengthened dialysis filter lifespan, the RICH trial found.

In this randomized trial of 638 patients receiving continuous kidney replacement therapy, anticoagulation with regional citrate lengthened filter lifespan by an average of 11.2 hours (95% CI 8.2-14.3 hours, P<0.001) versus systemic heparin anticoagulation, according to Alexander Zarbock, MD, of Universitatsklinikum Munster in Germany.

Sotagliflozin Prevents Heart Events in Acute HF, Chronic Kidney Disease

Novel SGLT1 and SGLT2 inhibitor sotagliflozin reduced cardiovascular events in particularly high-risk type 2 diabetes patients with worsening heart failure or chronic kidney disease, two trials showed.

LET'S START YOUR STUDY TODAY!